Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects, as Multiple Ascending Doses in COPD Subjects and Single Dose in Healthy Japanese Subjects

Next Previous
X
Search
Trial Profile

Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects, as Multiple Ascending Doses in COPD Subjects and Single Dose in Healthy Japanese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozorakimab (Primary) ; Tozorakimab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AstraZeneca; MedImmune

    • Most Recent Events

    • 12 Dec 2019 Status changed from active, no longer recruiting to completed.
    • 15 May 2019 Status changed from recruiting to active, no longer recruiting.
    • 13 Mar 2019 Planned End Date changed from 10 Sep 2019 to 30 Sep 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top